Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Sinemet
Immediate release carbidopa/levodopa · 1 trial · 1 indication
Dyskinesia was assessed by a blinded rater at each visit. Time to dyskinesia was defined as the visit at which the rater first answered "yes" to the following question: "In your opinion, does this patient have dyskinesia?" Time to dyskinesia was estimated by Kaplan-Meier product limit estimate that takes into consideration patients who did not experience dyskinesia by censoring them at the end of the study.
| Arm | Type | Description |
|---|---|---|
| Carbidopa/levodopa/entacapone | EXPERIMENTAL | Patients received Carbidopa/levodopa/entacapone tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks. |
| Immediate release carbidopa/levodopa | ACTIVE_COMPARATOR | Patients received Immediate release carbidopa/levodopa tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks. |
| Name | Type | Description |
|---|---|---|
| Carbidopa/levodopa/entacapone | DRUG | Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules. |
| Immediate release carbidopa/levodopa | DRUG | Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules. |
Inclusion Criteria: * Clinical diagnosis of idiopathic Parkinson's disease * Diagnosis of Parkinson's disease for no more than 5 years Exclusion Criteria: * History, signs, or symptoms of atypical or secondary parkinsonism * Presence at baseline of drug-related wearing-off symptoms, dyskinesia or...
Top 15 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| Bayer | BAYRY | 4 | PHASE3 | bemdaneprocel, AB-1005 |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Eli Lilly and Company | LLY | 4 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| Serina Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7568282 |
| Merck & Co., Inc. | MRK | 1 | EARLY_PHASE1 | MK-0947 |
Immediate release carbidopa/levodopa is used to treat Parkinson's disease. It is a small molecule therapy developed by Novartis AG (ticker: NVS) and has been studied in a Phase 3 clinical trial for patients with Parkinson's disease who require initiation of levodopa therapy.
Immediate release carbidopa/levodopa is developed by Novartis AG, which trades under the ticker symbol NVS. Novartis is the sponsor of the clinical development program for this Parkinson's disease therapy.
Immediate release carbidopa/levodopa is in Phase 3 clinical development. One Phase 3 trial has been completed, and there are currently no active trials listed for this drug. It is an investigational therapy and has not been approved by the FDA.
Immediate release carbidopa/levodopa has been studied in one completed Phase 3 trial, NCT00099268, titled "Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy." The trial enrolled 747 participants across multiple countries and was active-controlled and double-blind.